Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic/Locally Advanced Breast Cancer: PERTAIN Final Analysis

CONCLUSIONS: The PFS benefit of pertuzumab was maintained and OS was similar between arms at final analysis. Adding pertuzumab may enhance activity in patients who do not require first-line chemotherapy for M/LABC. No new safety concerns were reported. These data provide additional evidence of the role of first-line pertuzumab and trastuzumab in HER2-positive M/LABC.PMID:36716289 | DOI:10.1158/1078-0432.CCR-22-1092

Source: Clinical Genitourinary Cancer - January 30, 2023 Category: Cancer & Oncology Authors: Grazia Arpino Juan de la Haba-Rodr íguez Jean-Marc Ferrero Sabino De Placido C Kent Osborne Dirk Klingbiel Valentine Revelant Christine Wohlfarth Raf Poppe Mothaffar F Rimawi Source Type: research